Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients With Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

X
Trial Profile

A Pilot Study of Safety, Tolerability, and Immunological Effects of SurVaxM in Pediatric Patients With Progressive or Relapsed Medulloblastoma, High Grade Glioma, Ependymoma and Newly Diagnosed Diffuse Intrinsic Pontine Glioma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 May 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SVN53-67-M57-KLH peptide vaccine (Primary) ; Montanide ISA-51; Sargramostim
  • Indications Anaplastic astrocytoma; Astrocytoma; Diffuse intrinsic pontine glioma; Ependymoma; Glioblastoma; Glioma; Medulloblastoma; Meningeal carcinomatosis; Oligodendroglioma
  • Focus Adverse reactions
  • Most Recent Events

    • 10 Jan 2023 Planned End Date changed from 1 Jan 2028 to 30 Jun 2028.
    • 10 Jan 2023 Planned primary completion date changed from 1 Jul 2025 to 30 Aug 2025.
    • 24 May 2022 Status changed from active, no longer recruiting to recruiting.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top